LMP1/BARF1/EBNA1-Specific Cytotoxic T-Lymphocytes with or without Cyclophosphamide and Fludarabine in Treating Participants with EBV-Positive Lymphoma

Inclusion Criteria

• ELIGIBILITY FOR SCREENING: Any patient with diagnosis of either: * EBV positive Hodgkin’s lymphoma * EBV positive non-Hodgkin’s lymphoma (regardless of histologic subtype) * EBV (associated)-T/NK-lymphoproliferative disease * Severe chronic active EBV (CAEBV)** AND * In first or subsequent relapse (Group A) * With active disease persisting despite therapy (Group B) * With active disease if immunosuppressive chemotherapy is contraindicated e.g. patients who develop Hodgkin disease after solid organ transplantation or if the lymphoma is a second malignancy e.g. a Richter's transformation of chronic lymphocytic leukemia (CLL) (Group C) ** CAEBV is defined as patients with high EBV viral load in plasma or peripheral blood mononuclear cell (PBMC) (> 4000 genomes per ug PBMC deoxyribonucleic acid [DNA]) and/or biopsy tissue positive for EBV
• ELIGIBILITY FOR SCREENING: EBV positive tumor (can be pending)
• ELIGIBILITY FOR SCREENING: Weighs at least 12 kg
• ELIGIBILITY FOR SCREENING: Informed consent (and assent as applicable) obtained from patient/guardian
• ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Any patient with diagnosis# of either: * EBV positive Hodgkin’s lymphoma * EBV positive non-Hodgkin’s lymphoma (regardless of histologic subtype) * EBV (associated)-T/NK-lymphoproliferative disease * Severe chronic active EBV (CAEBV)** AND# * In first or subsequent relapse (Group A) * With active disease persist despite therapy (Group B) * With active disease if immunosuppressive chemotherapy is contraindicated e.g. patients who develop Hodgkin disease after solid organ transplantation or if the lymphoma is a second malignancy e.g. a Richter's transformation of CLL (Group C) ** CAEBV is defined as patients with high EBV viral load in plasma or PBMC (> 4000 genomes per ug PBMC DNA) and/or biopsy tissue positive for EBV # The disease diagnosis and the group must be noted on the eligibility checklist
• ELIGIBILITY CRITERIA AT TIME OF TREATMENT: EBV positive tumor
• ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Patients with life expectancy ≥ 6 weeks
• ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Patients with bilirubin ≤ 3 x upper limit of normal
• ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Aspartate aminotransferase (AST) ≤ 5 x upper limit of normal
• ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Hemoglobin (Hgb) > 8.0 (may be a transfused value)
• ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Patients with a creatinine ≤ 2 x upper limit of normal for age
• ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Pulse oximetry of > 90% on room air
• ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Patients should have been off other investigational therapy for 30 days prior to infusion
• ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Patients with a Karnofsky/Lansky score of ≥ 50
• ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condom
• ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Informed consent (and assent as applicable) signed by patient/guardian

Exclusion Criteria

• Pregnant or lactating
• Severe intercurrent infection
• Current use of systemic corticosteroids > 0.5 mg/kg/day
• Patients who have received anti-thymocyte globulin (ATG), Campath, or other immunosuppressive T cell monoclonal antibodies within 30 days